Prime Medicine, Inc. (PRME)

Market Cap	591.45M +130.5%
Revenue (ttm)	4.63M +55.3%
Net Income	-201.14M
EPS	-1.35
Shares Out	177.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,149,976
Open	3.310
Previous Close	3.320
Day's Range	3.290 - 3.495
52-Week Range	1.110 - 6.940
Beta	2.67
Analysts	Buy
Price Target	7.56 (+126.35%)
Earnings Date	May 7, 2026

About PRME

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular in...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 20, 2022
• Employees: 146
• Stock Exchange: NASDAQ
• Ticker Symbol: PRME
• Website: https://primemedicine.com

Financial Performance

In 2025, Prime Medicine's revenue was $4.63 million, an increase of 55.28% compared to the previous year's $2.98 million. Losses were -$201.14 million, 2.69% more than in 2024.

Analyst Summary

According to 6 analysts, the average rating for PRME stock is "Buy." The 12-month stock price target is $7.56, which is an increase of 126.35% from the latest price.

Price Target

$7.56

(126.35% upside)

Analyst Consensus: Buy